Investigation of Treatment Effectiveness and Appropriateness for Primary Thyroid Lymphoma Using Japanese National Cancer Registry Data

Investigation of Treatment Effectiveness and Appropriateness for Primary Thyroid Lymphoma Using Japanese National Cancer Registry Data - National Thyroid Lymphoma Research (NTLR)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000055619

Enrollment

2500

Registered

2024-09-26

Start date

2024-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary Thyroid Lymphoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients registered in the national cancer registry between 2016 and 2020, classified under ICD-O-3 as LYMPHOID NEOPLASMS, with localization codes C73.9 (thyroid primary) or other than C73.9 and C42.1.

Exclusion criteria

Exclusion criteria: Cases with a histological diagnosis other than primary thyroid lymphoma, or cases with a survival time of 0 days from the date of diagnosis.

Design outcomes

Primary

Measure	Time frame
Overall survival (OS)	—

Secondary

Measure	Time frame
Disease-specific survival, 90-day and 180-day mortalities from diagnosis, incidence of secondary cancers, and treatment choice trends by region.	—

Countries

Japan

Contacts

Public ContactYoshiyuki Saito

Ito hospital Department of Surgery

y-saito@ito-hospital.jp+81-3-3402-7411

Outcome results